Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort
出版年份 2020 全文链接
标题
Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort
作者
关键词
-
出版物
Scientific Reports
Volume 10, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-11-19
DOI
10.1038/s41598-020-76975-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells
- (2020) Hongge Wang et al. ONCOGENE
- Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy
- (2020) Daniel R Principe et al. CANCER RESEARCH
- ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
- (2020) Nicholas R. Jette et al. Cancers
- MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma
- (2020) David King et al. Oncotarget
- Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant
- (2020) Sherko Kuemmel et al. npj Breast Cancer
- DNA Polymerase theta (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse
- (2019) Zi Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
- (2019) Patrick G. Pilié et al. CLINICAL CANCER RESEARCH
- Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
- (2019) Paul Lesueur et al. BMC CANCER
- PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma
- (2019) de Koning et al. Cancers
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL
- (2019) Salma Parvin et al. CANCER CELL
- Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
- (2019) Anna F. Farago et al. Cancer Discovery
- Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib
- (2019) Daniel R. Principe et al. ONCOLOGIST
- The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma
- (2019) Samuel C. Fehling et al. CANCER LETTERS
- PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation
- (2019) Shun-ichiro Kageyama et al. JOURNAL OF RADIATION RESEARCH
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
- (2019) Joaquin Mateo et al. LANCET ONCOLOGY
- Biomarkers for Homologous Recombination Deficiency in Cancer
- (2018) Michal M Hoppe et al. JNCI-Journal of the National Cancer Institute
- Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent
- (2018) Steven T. Sizemore et al. MOLECULAR CANCER RESEARCH
- Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
- (2018) Alan Ashworth et al. Nature Reviews Clinical Oncology
- Biomarkers for Homologous Recombination Deficiency in Cancer
- (2018) Michal M Hoppe et al. JNCI-Journal of the National Cancer Institute
- PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation
- (2018) Yize Mao et al. Cancer Medicine
- Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer
- (2018) Dong Hou et al. Redox Biology
- PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer
- (2018) Yu Jiang et al. INTERNATIONAL JOURNAL OF CANCER
- A phase I/II trial adding poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel (Carbo-Tax) in patients with head and neck squamous cell carcinoma (HNSCC) Alliance A091101.
- (2018) Michael J. Jelinek et al. JOURNAL OF CLINICAL ONCOLOGY
- High speed of fork progression induces DNA replication stress and genomic instability
- (2018) Apolinar Maya-Mendoza et al. NATURE
- BRCA1/2 mutations are not a common cause of malignant melanoma in the Polish population
- (2018) Tadeusz Dębniak et al. PLoS One
- Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
- (2018) RR Bonadio et al. Clinics
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
- (2017) Arnab Ray Chaudhuri et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
- (2017) X Bian et al. ONCOGENE
- ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib
- (2017) Chen Wang et al. Translational Oncology
- PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis
- (2017) Christine Dinkic et al. Oncology Letters
- Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes
- (2017) Nadeem Riaz et al. Nature Communications
- Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions
- (2017) Susan M. Domchek Cancer Discovery
- Trastuzumab in the Treatment of Breast Cancer
- (2016) Sofia Maximiano et al. BIODRUGS
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
- (2015) Raphael Ceccaldi et al. NATURE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
- (2014) Aki Miyasaka et al. BMC CANCER
- Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines
- (2014) Eiji Kubota et al. CELL CYCLE
- Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program:PALB2mutation predicts exceptionalin vivoresponse to BMN 673
- (2014) Malcolm A. Smith et al. PEDIATRIC BLOOD & CANCER
- A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
- (2013) Ruth Plummer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- PARP-1 Regulates Metastatic Melanoma through Modulation of Vimentin-induced Malignant Transformation
- (2013) María Isabel Rodríguez et al. PLoS Genetics
- Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
- (2012) A.-M. Tsimberidou et al. CLINICAL CANCER RESEARCH
- Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
- (2012) Chris T. Williamson et al. EMBO Molecular Medicine
- On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1
- (2012) X. Luo et al. GENES & DEVELOPMENT
- PARP Inhibitors in Lung Cancer
- (2012) David R. Spigel Journal of Thoracic Oncology
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
- (2011) M. Fraser et al. CLINICAL CANCER RESEARCH
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo
- (2010) V. J. Weston et al. BLOOD
- BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review
- (2010) Xin An et al. LEUKEMIA RESEARCH
- ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
- (2010) C. T. Williamson et al. MOLECULAR CANCER THERAPEUTICS
- Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination
- (2010) Rémi Buisson et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
- (2010) K. J. Dedes et al. Science Translational Medicine
- Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors
- (2009) Ana M. Mendes-Pereira et al. EMBO Molecular Medicine
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started